Remove 2027 Remove Communication Remove Packaging
article thumbnail

FDA Approves Immunoglobulin Formulation With Low IgA Content for Primary Immunodeficiency

Pharmacy Times

Takeda will discontinue Gammagard S/D by December 2027, transitioning to the new low IgA formulation. Takeda has informed the FDA that the manufacturing of Gammagard S/D will cease in December 2027.

FDA 97
article thumbnail

Piramal Pharma announces $90m investment to expand US sites

Pharmaceutical Technology

The expansion will be concluded by late 2027, with production capacity increasing from 104 batches annually at peak utilisation to more than 240 batches. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address. Sign up for our daily news round-up!

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Merck concludes SpringWorks acquisition for $3.4bn

Pharmaceutical Technology

The merger, announced in April 2025 , will positively impact Merck’s financial position by contributing to revenues immediately, and is anticipated to be accretive to its earnings per share by 2027. How will RFK Jr’s American dream for vaccines play out? Give your business an edge with our leading industry insights.

article thumbnail

Vor Bio back from brink with autoimmune drug deal rising to $4bn

Pharmaceutical Technology

The study, which is expected to produce initial results in the first half of 2027, will support potential approval in the US and Europe. By GlobalData Learn more about Strategic Intelligence RemeGen is conducting a global Phase III clinical trial with telitacicept for the treatment of generalised myasthenia gravis.

article thumbnail

BioOrbit eyes 2026 for pre-clinical trials of space manufactured protein crystals

Pharmaceutical Technology

Then, we will need to run pre-clinical trials of these crystals, which will be in 2026 or 2027. Then the next step is to produce meaningful quantities of these crystals, which will be next year.” After that, it will be about compliance and regulation, as we must ensure that all our processes adhere to pharma regulations.

article thumbnail

FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency

Pharmaceutical Technology

Takeda anticipates commencing commercialisation efforts for Gammagard liquid ERC in the US by 2026, with plans to follow suit in the European Union (EU) by 2027. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard.

FDA 52
article thumbnail

WHO endorses Gilead’s Yeztugo for HIV prevention

Pharmaceutical Technology

Member states of the organisation agreed earlier this year to pay 20% more in membership fees to stopgap the US funding shortfall, though WHO’s overall budget for 2026-2027 will be lower than that for 2024-2025. How will RFK Jr’s American dream for vaccines play out? Sign up for our daily news round-up!